[Expression of CD10 and renal cell carcinoma marker in clear cell renal cell carcinoma: analysis on tissue arrays].
OBJECTIVE
CD10 and renal cell carcinoma (RCC) marker antibodies react against proteins of the epithelium of the renal proximal tubule, being expressed by renal cell carcinomas. The frequence and pattern of expression of both markers are analysed in a series of clear cell renal cell carcinomas.


METHODS
Two tissue arrays were used, which were composed of cylinders obtained with a 16G needle from 40 paraffin blocks that corresponded to clear cell renal cell carcinomas. The labeled streptavidin-biotin technique was performed (LSAB2, Dako) using CD10 and RCC monoclonal antibodies (Novocastra), testing different antigen retrieval methods for RCC. Immunoreactivity was evaluated as + (isolated cells or focal staining); ++ (moderate) and +++ (extense).


RESULTS
Thirty cases (75%) were positive for CD10: 12 +; 5 ++ and 13 +++. The best antigen retrieval method for RCC was a double enzyme digestion (trypsin + protease). Twenty cases (50%) were positive for RCC: 7 +; 5 ++ and 8 +++. Four cases out of the 20 immunoreactive for RCC were negative for CD10. The 16 remaining cases also expressed CD10.


CONCLUSIONS
CD10 and RCC are often expressed by clear cell renal cell carcinomas, and they may be useful markers to suggest a renal origin of carcinomas. RCC is less sensitive than CD10. Staining for both of them is usually focal, and thus sensitivity of these techniques decreases when small samples are investigated, such as tissue arrays. The antigen retrieval method is essential for RCC immunohistochemical detection, obtaining the best results with the use of proteolytic enzymes.
Ortiz-Rey
J A
JA
Servicio de Patología, Hospital POVISA, Vigo (Pontevedra). jaortiz@povisa.es
Gómez De María
C
C
Peláez Boismorand
E
E
Fernández Costas
A
A
Barbosa Barreiro
M J
MJ
Antón Badiola
I
I
D014408:Biomarkers, Tumor / Q000032:analysis / Q000096:biosynthesis*; D002292:Carcinoma, Renal Cell / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology*; D006801:Humans; D007680:Kidney Neoplasms / Q000737:chemistry / Q000378:metabolism* / Q000473:pathology*; D015260:Neprilysin / Q000032:analysis / Q000096:biosynthesis*; D012680:Sensitivity and Specificity; D046888:Tissue Array Analysis
D014408:Biomarkers, Tumor; D015260:Neprilysin